Search Results - "Diaz, Luis A."

Liquid Biopsies: Genotyping Circulating Tumor DNA by DIAZ, Luis A, BARDELLI, Alberto

“…Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these…”
Get full text

Immunotherapy in colorectal cancer: rationale, challenges and potential by Ganesh, Karuna, Stadler, Zsofia K., Cercek, Andrea, Mendelsohn, Robin B., Shia, Jinru, Segal, Neil H., Diaz, Luis A.

“…Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid…”
Get full text

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 by Le, Dung T, Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O'Neil, Bert, Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Elez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M, Crocenzi, Todd, Atreya, Chloe E, Cui, Yi, Dai, Tong, Marinello, Patricia, Diaz, Jr, Luis A, André, Thierry

“…KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch…”
Get full text

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells by Kim, KiBem, Skora, Andrew D., Li, Zhaobo, Liu, Qiang, Tam, Ada J., Blosser, Richard L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin

“…Impressive responses have been observed in patients treated with checkpoint inhibitory anti–programmed cell death-1 (PD-1) or anti–cytotoxic…”
Get full text

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors by Rousseau, Benoit, Foote, Michael B, Maron, Steven B, Diplas, Bill H, Lu, Steve, Argilés, Guillem, Cercek, Andrea, Diaz, Luis A

“…The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA. This study showed…”
Get full text

Cancer Genome Landscapes by Vogelstein, Bert, Papadopoulos, Nickolas, Velculescu, Victor E., Zhou, Shibin, Diaz, Luis A., Kinzler, Kenneth W.

“…Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this…”
Get full text

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade by Lee, Valerie, Murphy, Adrian, Le, Dung T., Diaz, Luis A.

“…More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the…”
Get full text

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers by Diaz Jr, Luis A., Williams, Richard T., Wu, Jian, Kinde, Isaac, Hecht, J. Randolph, Berlin, Jordan, Allen, Benjamin, Bozic, Ivana, Reiter, Johannes G., Nowak, Martin A., Kinzler, Kenneth W., Oliner, Kelly S., Vogelstein, Bert

“…This work on colorectal cancer shows that secondary mutations in KRAS that confer resistance to panitumumab, an anti-EGFR monoclonal antibody, are already…”
Get full text

Heteroplasmic mitochondrial DNA mutations in normal and tumour cells by Vogelstein, Bert, Papadopoulos, Nickolas, He, Yiping, Wu, Jian, Dressman, Devin C, Iacobuzio-Donahue, Christine, Markowitz, Sanford D, Velculescu, Victor E, Diaz Jr, Luis A, Kinzler, Kenneth W

“…The presence of hundreds of copies of mitochondrial DNA (mtDNA) in each human cell poses a challenge for the complete characterization of mtDNA genomes by…”
Get full text

Circulating mutant DNA to assess tumor dynamics by Sokoll, Lori, Li, Meng, Agrawal, Nishant, Thornton, Katherine, Schmidt, Kerstin, Szabo, Steve A, Vogelstein, Bert, Diaz Jr, Luis A, Diehl, Frank, Romans, Katharine, Choti, Michael A, Goodman, Steven, Kinzler, Kenneth W

“…The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers for…”
Get full text

The genomic landscape of response to EGFR blockade in colorectal cancer by Bertotti, Andrea, Papp, Eniko, Jones, Siân, Adleff, Vilmos, Anagnostou, Valsamo, Lupo, Barbara, Sausen, Mark, Phallen, Jillian, Hruban, Carolyn A., Tokheim, Collin, Niknafs, Noushin, Nesselbush, Monica, Lytle, Karli, Sassi, Francesco, Cottino, Francesca, Migliardi, Giorgia, Zanella, Eugenia R., Ribero, Dario, Russolillo, Nadia, Mellano, Alfredo, Muratore, Andrea, Paraluppi, Gianluca, Salizzoni, Mauro, Marsoni, Silvia, Kragh, Michael, Lantto, Johan, Cassingena, Andrea, Li, Qing Kay, Karchin, Rachel, Scharpf, Robert, Sartore-Bianchi, Andrea, Siena, Salvatore, Diaz, Luis A., Trusolino, Livio, Velculescu, Victor E.

“…The effect of somatic genetic changes in colorectal cancer on sensitivity to anti-EGFR antibody therapy is analysed. Genomics of a cancer during targeted…”
Get full text

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways by Wu, Jian, Jiao, Yuchen, Dal Molin, Marco, Maitra, Anirban, de Wilde, Roeland F, Wood, Laura D, Eshleman, James R, Goggins, Michael G, Wolfgang, Christopher L, Canto, Marcia I, Schulick, Richard D, Edil, Barish H, Choti, Michael A, Adsay, Volkan, Klimstra, David S, Offerhaus, G. Johan A, Klein, Alison P, Kopelovich, Levy, Carter, Hannah, Karchin, Rachel, Allen, Peter J, Schmidt, C. Max, Naito, Yoshiki, Diaz, Luis A. Jr, Kinzler, Kenneth W, Papadopoulos, Nickolas, Hruban, Ralph H, Vogelstein, Bert

“…More than 2% of adults harbor a pancreatic cyst, a subset of which progresses to invasive lesions with lethal consequences. To assess the genomic landscapes of…”
Get full text

Direct detection of early-stage cancers using circulating tumor DNA by Phallen, Jillian, Sausen, Mark, Adleff, Vilmos, Leal, Alessandro, Hruban, Carolyn, White, James, Anagnostou, Valsamo, Fiksel, Jacob, Cristiano, Stephen, Papp, Eniko, Speir, Savannah, Reinert, Thomas, Orntoft, Mai-Britt Worm, Woodward, Brian D, Murphy, Derek, Parpart-Li, Sonya, Riley, David, Nesselbush, Monica, Sengamalay, Naomi, Georgiadis, Andrew, Li, Qing Kay, Madsen, Mogens Rørbæk, Mortensen, Frank Viborg, Huiskens, Joost, Punt, Cornelis, van Grieken, Nicole, Fijneman, Remond, Meijer, Gerrit, Husain, Hatim, Scharpf, Robert B, Diaz, Jr, Luis A, Jones, Siân, Angiuoli, Sam, Ørntoft, Torben, Nielsen, Hans Jørgen, Andersen, Claus Lindbjerg, Velculescu, Victor E

“…Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of…”
Get more information

From neoadjuvant to organ-sparing immunotherapy for colorectal cancer by Rousseau, Benoit, Cercek, Andrea, Diaz, Luis A.

“…In a new study, neoadjuvant immunotherapy led to major pathological responses in patients with locally advanced colon cancer harboring mismatch repair…”
Get full text

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors by Jiao, Yuchen, Shi, Chanjuan, Edil, Barish H, de Wilde, Roeland F, Klimstra, David S, Maitra, Anirban, Schulick, Richard D, Tang, Laura H, Wolfgang, Christopher L, Choti, Michael A, Velculescu, Victor E, Diaz, Luis A. Jr, Vogelstein, Bert, Kinzler, Kenneth W, Hruban, Ralph H, Papadopoulos, Nickolas

“…Pancreatic neuroendocrine tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we…”
Get full text

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial by Andre, Thierry, Amonkar, Mayur, Norquist, Josephine M, Shiu, Kai-Keen, Kim, Tae Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis J A, Smith, Denis, Garcia-Carbonero, Rocio, Sevilla, Isabel, De La Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Diaz, Luis A, Yoshino, Takayuki, Van Cutsem, Eric, Yang, Ping, Farooqui, Mohammed, Le, Dung T

“…In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival…”
Get full text

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity by Lu, Changzheng, Guan, Junhong, Lu, Steve, Jin, Qihuang, Rousseau, Benoit, Lu, Tianshi, Stephens, Dennis, Zhang, Hongyi, Zhu, Jiankun, Yang, Mingming, Ren, Zhenhua, Liang, Yong, Liu, Zhida, Han, Chuanhui, Liu, Longchao, Cao, Xuezhi, Zhang, Anli, Qiao, Jian, Batten, Kimberly, Chen, Mingyi, Castrillon, Diego H., Wang, Tao, Li, Bo, Diaz, Luis A., Li, Guo-Min, Fu, Yang-Xin

“…Increased neoantigens in hypermutated cancers with DNA mismatch repair deficiency (dMMR) are proposed as the major contributor to the high objective response…”
Get full text

Evolutionary dynamics of cancer in response to targeted combination therapy by Bozic, Ivana, Reiter, Johannes G, Allen, Benjamin, Antal, Tibor, Chatterjee, Krishnendu, Shah, Preya, Moon, Yo Sup, Yaqubie, Amin, Kelly, Nicole, Le, Dung T, Lipson, Evan J, Chapman, Paul B, Diaz, Jr, Luis A, Vogelstein, Bert, Nowak, Martin A

“…In solid tumors, targeted treatments can lead to dramatic regressions, but responses are often short-lived because resistant cancer cells arise. The major…”
Get full text

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations by Hu, Zishuo I, Shia, Jinru, Stadler, Zsofia K, Varghese, Anna M, Capanu, Marinela, Salo-Mullen, Erin, Lowery, Maeve A, Diaz, Jr, Luis A, Mandelker, Diana, Yu, Kenneth H, Zervoudakis, Alice, Kelsen, David P, Iacobuzio-Donahue, Christine A, Klimstra, David S, Saltz, Leonard B, Sahin, Ibrahim H, O'Reilly, Eileen M

“…Immune checkpoint inhibition has been shown to generate profound and durable responses in mismatch repair deficient (MMR-D) solid tumors and has elicited…”
Get full text

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells by Yun, Jihye, Rago, Carlo, Cheong, Ian, Pagliarini, Ray, Angenendt, Philipp, Rajagopalan, Harith, Schmidt, Kerstin, Willson, James K.V, Markowitz, Sandy, Zhou, Shibin, Diaz, Luis A. Jr, Velculescu, Victor E, Lengauer, Christoph, Kinzler, Kenneth W, Vogelstein, Bert, Papadopoulos, Nickolas

“…Tumor progression is driven by genetic mutations, but little is known about the environmental conditions that select for these mutations. Studying the…”
Get full text